177 related articles for article (PubMed ID: 37120435)
1. Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer.
Yue W; Yupeng G; Jun C; Kui J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8681-8689. PubMed ID: 37120435
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer.
Hong T; Lei G; Chen X; Li H; Zhang X; Wu N; Zhao Y; Zhang Y; Wang J
Redox Biol; 2021 Jun; 42():101928. PubMed ID: 33722571
[TBL] [Abstract][Full Text] [Related]
3. Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway.
Xia L; Gong M; Zou Y; Wang Z; Wu B; Zhang S; Li L; Jin K; Sun C
Oxid Med Cell Longev; 2022; 2022():9925919. PubMed ID: 35602105
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
Wang Z; Gao J; Ohno Y; Liu H; Xu C
Cancer Chemother Pharmacol; 2020 Feb; 85(2):273-284. PubMed ID: 31907647
[TBL] [Abstract][Full Text] [Related]
5. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer.
Wang Z; Gao J; Zhou J; Liu H; Xu C
J Gynecol Oncol; 2019 Mar; 30(2):e26. PubMed ID: 30740957
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
8. Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.
Tang S; Shen Y; Wei X; Shen Z; Lu W; Xu J
Cell Death Dis; 2022 Sep; 13(9):826. PubMed ID: 36163324
[TBL] [Abstract][Full Text] [Related]
9. [IL-1β inhibitor sensitizes to olaparib in homologous recombination deficiency proficient ovarian cancer cells].
Xu JF; Cen YX; Tang SS; Ren Y; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2022 Jul; 57(7):519-529. PubMed ID: 35902786
[No Abstract] [Full Text] [Related]
10. Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells.
Sun X; Li J; Li Y; Wang S; Li Q
Oxid Med Cell Longev; 2020; 2020():3145182. PubMed ID: 32509141
[TBL] [Abstract][Full Text] [Related]
11. p53 Promoted Ferroptosis in Ovarian Cancer Cells Treated with Human Serum Incubated-Superparamagnetic Iron Oxides.
Zhang Y; Xia M; Zhou Z; Hu X; Wang J; Zhang M; Li Y; Sun L; Chen F; Yu H
Int J Nanomedicine; 2021; 16():283-296. PubMed ID: 33469287
[TBL] [Abstract][Full Text] [Related]
12. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
Vescarelli E; Gerini G; Megiorni F; Anastasiadou E; Pontecorvi P; Solito L; De Vitis C; Camero S; Marchetti C; Mancini R; Benedetti Panici P; Dominici C; Romano F; Angeloni A; Marchese C; Ceccarelli S
J Exp Clin Cancer Res; 2020 Jan; 39(1):3. PubMed ID: 31898520
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
14. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
15. Chelerythrine induces apoptosis and ferroptosis through Nrf2 in ovarian cancer cells.
Zhou J; Wang Y; Fu Y; Lin Z; Lin H; Lv G; Kong N; Xin G; Zhou F; Qiu Z; Huang X
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):174-181. PubMed ID: 38650145
[TBL] [Abstract][Full Text] [Related]
16. mRNA-Modified FUS/NRF2 Signalling Inhibits Ferroptosis and Promotes Prostate Cancer Growth.
Wang N; Yu Y; Wang R; Chen Y; Tang J
Comput Math Methods Med; 2022; 2022():8509626. PubMed ID: 36035281
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
[TBL] [Abstract][Full Text] [Related]
18. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
19. Apatinib induced ferroptosis by lipid peroxidation in gastric cancer.
Zhao L; Peng Y; He S; Li R; Wang Z; Huang J; Lei X; Li G; Ma Q
Gastric Cancer; 2021 May; 24(3):642-654. PubMed ID: 33544270
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]